Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | RHEB | Q15382 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30501981 | 0.87 | BRD4 (0.48) | BRD4LRRK2NPC1RAB9AHPGD | |
| SCHEMBL4662927 | 0.87 | BRD4 (0.48) | BRD4SRD5A2LRRK2SRD5A1NPC1 | |
| SCHEMBL4663172 | 0.86 | BRD4 (0.47) | BRD4SRD5A2LRRK2SRD5A1NPC1 | |
| SCHEMBL5901876 | 0.86 | CYP3A4 (0.39) | BRD4HPGDALDH1A1 | |
| SCHEMBL5901935 | 0.86 | HPGD (0.51) | SRD5A2SRD5A1NPC1RAB9AHPGD | |
| SCHEMBL4664610 | 0.85 | BRD4 (0.47) | BRD4SRD5A2LRRK2SRD5A1NPC1 | |
| SCHEMBL4666497 | 0.85 | BRD4 (0.47) | BRD4SRD5A2LRRK2SRD5A1NPC1 | |
| SCHEMBL5901336 | 0.85 | PPIA (0.47) | SRD5A2SRD5A1NPC1RAB9AHPGD | |
| SCHEMBL4663183 | 0.85 | MCHR1 (0.48) | BRD4SRD5A2LRRK2SRD5A1NPC1 | |
| SCHEMBL3267227 | 0.83 | BRD4 (0.45) | BRD4LRRK2NPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1575924-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA Pharma AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004054984-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | BRD4 85/4885SRD5A2 1668/4885LRRK2 3602/4885 |
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | GIPR, VIP, SI | BRD4 504/4885SRD5A2 469/4885LRRK2 2983/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | BRD4 1068/4885SRD5A2 2674/4885LRRK2 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.